Compare VPG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | KMDA |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 488.6M |
| IPO Year | 2010 | 2013 |
| Metric | VPG | KMDA |
|---|---|---|
| Price | $60.27 | $8.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $53.50 | $14.00 |
| AVG Volume (30 Days) | ★ 208.0K | 43.3K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $307,202,000.00 | N/A |
| Revenue This Year | $7.21 | $13.94 |
| Revenue Next Year | $6.92 | $9.84 |
| P/E Ratio | $143.95 | ★ $24.59 |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $21.31 | $6.35 |
| 52 Week High | $59.91 | $9.35 |
| Indicator | VPG | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 79.48 | 44.41 |
| Support Level | $38.13 | $7.96 |
| Resistance Level | N/A | $8.50 |
| Average True Range (ATR) | 2.42 | 0.18 |
| MACD | 1.06 | -0.01 |
| Stochastic Oscillator | 93.04 | 18.37 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.